Disease | multiple sclerosis |
Symptom | C0235946|brain atrophy |
Sentences | 10 |
PubMedID- 25756363 | Background: the aim of the present meta-analysis was to evaluate the effect of disease-modifying drugs (dmd) on brain atrophy in patients with relapsing-remitting multiple sclerosis (rrms) using available randomized-controlled trial (rct) data. |
PubMedID- 25941537 | Background: studies have shown a relationship between increased iron content and clinical progression, cognitive impairment, and brain atrophy in patients with multiple sclerosis. |
PubMedID- 23730365 | Over the last decade brain atrophy in patients with multiple sclerosis (ms) has found increasing interest. |
PubMedID- 26419927 | Fingolimod (fty720) reduces relapses, disability progression, and brain atrophy in patients with relapsing-remitting multiple sclerosis (ms) . |
PubMedID- 26362893 | Increased albumin quotient (qalb) in patients after first clinical event suggestive of multiple sclerosis is associated with development of brain atrophy and greater disability 48 months later. |
PubMedID- 22899026 | Oligoclonal bands in the cerebrospinal fluid and increased brain atrophy in early stages of relapsing-remitting multiple sclerosis. |
PubMedID- 21414412 | Regional brain atrophy in children with multiple sclerosis. |
PubMedID- 24022394 | In recent years, it has become increasingly evident that multiple sclerosis (ms) leads to clinically relevant brain atrophy in the disease course and that this process may begin early.1–10 the clinical correlate of brain atrophy, for example, can be a secondary chronic progression or pure neuropsychological discomfort or symptoms. |
PubMedID- 24264439 | brain atrophy: an in-vivo measure of disease activity in multiple sclerosis. |
PubMedID- 23650470 | A recent nih study by borges et al demonstrated a decrease in the rate of brain atrophy in patients with multiple sclerosis on daclizumab compared to placebo by assessing brain volume on t1-weighted and t2-flair mri sequences using toads-cruise program. |
Page: 1